A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease

Study Purpose

The goal of this clinical trial is to assess the safety and tolerability profile of belantamab. The study will also assess how the levels of belantamab change over time and body's reaction to it in participants with stable but active autoimmune disease.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Body mass index (BMI) from 18 to 40 kilograms per square meter (kg/m^2) (BMI = weight/height^2), inclusive, and body weight of >=40 kilogram (kg) - IgM >= lower limit of normal (LLN) (40 milligram per deciliter [mg/dL]) at initial screening visit (ISV).
Participants with systemic lupus erythematosus (SLE) must also meet the following

inclusion criteria:

  • - Documented clinical diagnosis of SLE according to the European League Against Rheumatism (EULAR) or American College of Rheumatology (ACR) Classification Criteria.
  • - Positive anti-double stranded deoxyribonucleic acid (anti-dsDNA) autoantibody and/or positive antinuclear antibody (ANA) test results, using central lab test, at ISV.
Participants with Rheumatoid Arthritis (RA) must also meet the following inclusion Criteria:
  • - Meets ACR/EULAR 2010 RA Classification Criteria with a duration of RA disease of >=6 months at time of ISV.
  • - Participants may be receiving treatment with a stable oral RA treatment regimen (which may include immunosuppressants, steroids [<=10 mg/day] and/or non-steroidal anti-inflammatory drugs) for at least 4 weeks before ISV.
Participants with antiphospholipid syndrome (APS) must also meet the following inclusion criteria:
  • - Documented diagnosis of APS meeting the 2023 ACR/EULAR APS classification criteria.
  • - Positive lupus anticoagulant test or moderate to high titers of positive IgG/IgM anticardiolipin (aCL) or moderate to high titers of IgG/Ig anti-beta2-glycoprotein I antibody using central lab test, at ISV.
  • - Sex and Contraceptive /Barrier requirements for females.

Exclusion Criteria:

SLE specific exclusion:
  • - Any acute, severe lupus related flare during the Screening Period that needs immediate treatment.
  • - Has any unstable or progressive manifestation of SLE.
  • - Significant, likely irreversible organ damage related to SLE.
RA specific exclusions:
  • - RA functional status class IV according to the ACR 1991 revised criteria.
  • - Adult Juvenile RA.
APS specific exclusions: - Acute thrombosis (arterial or venous acute thrombosis diagnosis less than 30 days before study ISV) - Catastrophic APS classification within the prior 90 days of ISV

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06413511
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

GlaxoSmithKline
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

GSK Clinical Trials
Principal Investigator Affiliation GlaxoSmithKline
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Spain, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Autoimmune Diseases
Arms & Interventions

Arms

Experimental: Belantamab

Interventions

Biological: - Belantamab

Belantamab will be administered

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

GSK Investigational Site, Medley, Florida

Status

Recruiting

Address

GSK Investigational Site

Medley, Florida, 33166

Site Contact

US GSK Clinical Trials Call Center

[email protected]

877-379-3718

GSK Investigational Site, Peachtree Corners, Georgia

Status

Recruiting

Address

GSK Investigational Site

Peachtree Corners, Georgia, 30071

Site Contact

US GSK Clinical Trials Call Center

[email protected]

877-379-3718

International Sites

GSK Investigational Site, Madrid, Spain

Status

Recruiting

Address

GSK Investigational Site

Madrid, , 28040

Site Contact

US GSK Clinical Trials Call Center

[email protected]

877-379-3718